CAR-T cell therapy has brought great hope to patients suffering from blood cancers. However, bringing such cutting-edge technology to market has its own set of challenges. How can we anticipate and mitigate risks in CAR-T cell therapy clinical trials to ensure this revolutionary therapy is appropriately trialed and can benefit a larger group of patients?